ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 151 | 4 | 166 | +19 |
| Shares | 64.1M | 573.2K | 71.3M | +7.82M (+12.3%) |
| Value | $928.4M | $6.59M | $752.3M | −$169.5M (−18.4%) |
4 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (38)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (19)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 536,900 | $7.79M |
| EAM Investors, LLC | 261,649 | $3.79M |
| K2 Principal Fund, L.P. | 120,000 | $1.74M |
| Brandywine Global Investment Management, LLC | 106,400 | $1.59M |
| Alps Advisors Inc | 70,578 | $1.02M |
| Caption Management, LLC | 64,700 | $938.1K |
| TD Asset Management Inc | 60,200 | $862.1K |
| Brevan Howard Capital Management LP | 32,921 | $477.4K |
| Campbell & CO Investment Adviser LLC | 21,446 | $311.0K |
| J.W. Cole Advisors, Inc. | 20,520 | $297.5K |
| Renaissance Technologies LLC | 15,800 | $229.1K |
| Quarry LP | 12,000 | $174.0K |
| Acadian Asset Management LLC | 4,009 | $58.0K |
| nVerses Capital, LLC | 2,100 | $30.4K |
| Catalyst Funds Management Pty Ltd | 2,000 | $29.0K |
| Pension & Wealth Management Advisors, Inc. | 73 | $1.07K |
| Capital Performance Advisors LLP | 33 | $479 |
| SRS Capital Advisors, Inc. | 22 | $319 |
| National Bank of Canada | 1 | $14 |
Not filed for Q4 2024 yet (4)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 204,783 | $2.97M |
| ClariVest Asset Management LLC | 287,596 | $2.45M |
| Raymond James Financial Services Advisors, Inc. | 78,779 | $1.14M |
| FinTrust Capital Advisors, LLC | 2,000 | $29.0K |